Endotracheal Poractant Alfa Not Effective in Critical Bronchiolitis

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Carmen Pope, BPharm. Last updated on April 2, 2026.

via HealthDay

THURSDAY, April 2, 2026 -- For infants with early critical bronchiolitis, endotracheal poractant alfa does not reduce the duration of invasive mechanical ventilation compared with a sham intervention, according to a study published online March 21 in The Lancet Respiratory Medicine.

Malcolm G. Semple, Ph.D., from the University of Liverpool in the United Kingdom, and colleagues conducted a randomized, sham-controlled, parallel-group, phase 2 trial to examine the safety and efficacy of endotracheal poractant alfa for treating critical bronchiolitis. The trial was conducted in 15 pediatric intensive care units; 232 infants were randomly assigned to receive up to three doses of endotracheal poractant alfa or a sham intervention (115 and 117, respectively).

Three infants were withdrawn from the study, and none were lost to follow-up. The researchers found that the median duration of invasive mechanical ventilation was 64.9 and 62.0 hours in the endotracheal poractant alfa group and the sham intervention group, respectively, for a geometric mean ratio of 1.02 (95 percent confidence interval, 0.84 to 1.24). There were no clinically significant safety issues seen in association with endotracheal poractant alfa, and no deaths were reported.

"The treatment was safe, but it didn't make any difference to how long babies stayed on ventilators. We had hoped that surfactant might speed up recovery for these very sick babies, but the evidence doesn't support this," Semple said in a statement.

One author disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-03 08:58

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords